MedTrace Logo

Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients

NCT00884039 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-08-14

Study results available
· View outcomes & findings →

Summary

This study will investigate the use of anecortave acetate injection to reduce intraocular pressure (IOP) in corneal transplant recipients who are experiencing steroid-associated pressure control problems. Alternative methods of IOP control have been shown to entail serious risks. For example, reduction of topical steroids increases the risk of graft rejection, and use of glaucoma medications or glaucoma surgery increases the risk of graft failure. This study is designed to have sufficient power to detect whether a single injection can induce a clinically significant IOP reduction.

Conditions

  • Transplant
  • Intraocular Pressure

Interventions

DRUG

anecortave acetate

anterior juxtascleral depot of 15 mg anecortave acetate

DRUG

30 mg anecortave acetate

anterior juxtascleral depot of 30mg anecortave acetate

Sponsors & Collaborators

  • Cornea Research Foundation of America

    lead OTHER

Principal Investigators

  • Francis W. Price, Jr., MD · Cornea Research Foundation of America

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-08-31
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00884039 on ClinicalTrials.gov